Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank87
5Y CAGR+0.5%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+0.5%/yr
Long-term compound
Percentile
P87
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 38.80% |
| Q3 2025 | 2.68% |
| Q2 2025 | 22.97% |
| Q1 2025 | -4.18% |
| Q4 2024 | 21.14% |
| Q3 2024 | -23.44% |
| Q2 2024 | 26.19% |
| Q1 2024 | 6.08% |
| Q4 2023 | -12.43% |
| Q3 2023 | 15.48% |
| Q2 2023 | 6.94% |
| Q1 2023 | -31.45% |
| Q4 2022 | -10.96% |
| Q3 2022 | 16.88% |
| Q2 2022 | 3.86% |
| Q1 2022 | -11.31% |
| Q4 2021 | 9.84% |
| Q3 2021 | 0.35% |
| Q2 2021 | -13.96% |
| Q1 2021 | -141.48% |
| Q4 2020 | 37.83% |
| Q3 2020 | 13.43% |
| Q2 2020 | -92.44% |
| Q1 2020 | -192.26% |
| Q4 2019 | 100.14% |
| Q3 2019 | 71.26% |
| Q2 2019 | 387.96% |
| Q1 2019 | -104.68% |
| Q4 2018 | -19.15% |
| Q3 2018 | 52.17% |
| Q2 2018 | 34.29% |
| Q1 2018 | 17.26% |
| Q4 2017 | -73.52% |
| Q3 2017 | 513.55% |
| Q2 2017 | -38.11% |
| Q1 2017 | -34.91% |
| Q4 2016 | -127.36% |
| Q3 2016 | -184.57% |
| Q2 2016 | -92.74% |
| Q1 2016 | -101.59% |